Morgan Stanley lowered the firm’s price target on NeoGenomics (NEO) to $8 from $10 and keeps an Equal Weight rating on the shares after Q2 revenue came in below expectations due to continued pharma softness and guidance was lowered to reflect biopharma headwinds and the delayed commercial launch of PanTracer LBx.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- NeoGenomics downgraded to Neutral from Buy at BTIG
- NeoGenomics Reports Revenue Growth Amid Rising Losses
- NeoGenomics: Potential Upside Amidst Challenges and Low Valuation
- NeoGenomics: Buy Rating Affirmed Amid Stable Growth and Strategic Focus Despite Near-Term Challenges
- William Blair downgrades NeoGenomics, says rebuilding credibility will take time